Insider Selling: Beta Bionics (NASDAQ:BBNX) CFO Sells 1,428 Shares of Stock

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 1,428 shares of Beta Bionics stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $12.36, for a total value of $17,650.08. Following the completion of the sale, the chief financial officer directly owned 172,729 shares in the company, valued at $2,134,930.44. This represents a 0.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Stephen Feider also recently made the following trade(s):

• On Friday, January 2nd, Stephen Feider sold 20,000 shares of Beta Bionics stock. The stock was sold at an average price of $29.53, for a total transaction of $590,600.00.

Beta Bionics Stock Performance

Shares of Beta Bionics stock traded down $0.95 during mid-day trading on Tuesday, hitting $11.57. The stock had a trading volume of 1,609,029 shares, compared to its average volume of 1,181,053. Beta Bionics, Inc. has a 12-month low of $8.89 and a 12-month high of $32.71. The firm has a 50-day moving average of $18.74 and a two-hundred day moving average of $22.43.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings results on Tuesday, February 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.12. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%. The business had revenue of $32.12 million for the quarter.

Analyst Ratings Changes

BBNX has been the subject of a number of recent research reports. Wall Street Zen lowered Beta Bionics from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Robert W. Baird dropped their price target on Beta Bionics from $28.00 to $14.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. UBS Group upgraded shares of Beta Bionics to a “strong-buy” rating in a research note on Monday, February 9th. Bank of America downgraded Beta Bionics from a “buy” rating to a “neutral” rating in a research report on Friday, January 9th. Finally, Lake Street Capital set a $20.00 price target on Beta Bionics in a report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.20.

Hedge Funds Weigh In On Beta Bionics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. GPS Wealth Strategies Group LLC grew its holdings in shares of Beta Bionics by 45.0% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock valued at $29,000 after acquiring an additional 450 shares in the last quarter. Strs Ohio acquired a new stake in shares of Beta Bionics in the first quarter worth $29,000. EverSource Wealth Advisors LLC lifted its position in shares of Beta Bionics by 203.6% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after purchasing an additional 1,594 shares during the last quarter. Summit Securities Group LLC acquired a new stake in shares of Beta Bionics in the fourth quarter worth $52,000. Finally, CWM LLC bought a new position in shares of Beta Bionics during the 2nd quarter worth about $58,000.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.